WO2025006830A3 - Composés pour le traitement de la rétinite pigmentaire et leurs procédés de fabrication et d'utilisation - Google Patents

Composés pour le traitement de la rétinite pigmentaire et leurs procédés de fabrication et d'utilisation Download PDF

Info

Publication number
WO2025006830A3
WO2025006830A3 PCT/US2024/035948 US2024035948W WO2025006830A3 WO 2025006830 A3 WO2025006830 A3 WO 2025006830A3 US 2024035948 W US2024035948 W US 2024035948W WO 2025006830 A3 WO2025006830 A3 WO 2025006830A3
Authority
WO
WIPO (PCT)
Prior art keywords
same
methods
compounds
making
retinitis pigmentosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/035948
Other languages
English (en)
Other versions
WO2025006830A2 (fr
Inventor
Sudeshna ROY
Mario DJUGOVSKI
Tzu-Yu Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Mississippi
Original Assignee
University of Mississippi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Mississippi filed Critical University of Mississippi
Publication of WO2025006830A2 publication Critical patent/WO2025006830A2/fr
Publication of WO2025006830A3 publication Critical patent/WO2025006830A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Selon un aspect, l'invention concerne des composés à base de cystéine et de sélénocystéine N-acétylés substitués. L'invention concerne également des procédés de fabrication de ceux-ci, des compositions pharmaceutiques les comprenant, et des méthodes de traitement de troubles oculaires comprenant la rétinite pigmentaire (RP) les utilisant. Selon certains aspects, les composés peuvent également présenter une activité antimicrobienne. Le présent abrégé est proposé à titre d'outil d'exploration à des fins de recherche dans la technique concernée et n'est pas destiné à limiter la portée de la présente invention.
PCT/US2024/035948 2023-06-28 2024-06-28 Composés pour le traitement de la rétinite pigmentaire et leurs procédés de fabrication et d'utilisation Ceased WO2025006830A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363510709P 2023-06-28 2023-06-28
US63/510,709 2023-06-28

Publications (2)

Publication Number Publication Date
WO2025006830A2 WO2025006830A2 (fr) 2025-01-02
WO2025006830A3 true WO2025006830A3 (fr) 2025-04-24

Family

ID=93940011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/035948 Ceased WO2025006830A2 (fr) 2023-06-28 2024-06-28 Composés pour le traitement de la rétinite pigmentaire et leurs procédés de fabrication et d'utilisation

Country Status (1)

Country Link
WO (1) WO2025006830A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018216823A1 (fr) * 2017-05-25 2018-11-29 Taisho Pharmaceutical Co., Ltd. Dérivés d'alpha-amino-amide
US11173135B2 (en) * 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173135B2 (en) * 2016-03-17 2021-11-16 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders
WO2018216823A1 (fr) * 2017-05-25 2018-11-29 Taisho Pharmaceutical Co., Ltd. Dérivés d'alpha-amino-amide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE PubChem 6 December 2019 (2019-12-06), "SID 388891440", XP093307634, Database accession no. SID 388891440 *

Also Published As

Publication number Publication date
WO2025006830A2 (fr) 2025-01-02

Similar Documents

Publication Publication Date Title
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
NZ539841A (en) Hydroxyethylamine derivatives for the treatment of alzheimer's disease
WO2024189598A3 (fr) Inhibiteurs de kat6a de type acylsulfonamides
WO2024006726A3 (fr) Composés utilisés en tant qu'inhibiteurs d'axl
MX2022015022A (es) Composiciones farmaceuticas de pralsetinib.
CA2148194A1 (fr) Cyclopeptides de formule i
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
WO2023122783A8 (fr) Tétrahydropyrazolopyrimidines et analogues associés pour inhiber yap/taz-tead
GEAP202516737A (en) Compounds for treating cancer
MX2023009166A (es) Derivados de quinoxalina y sus usos.
WO2022020114A3 (fr) Méthodes de prévention et de traitement de la perte d'audition
WO2023150790A3 (fr) Nouveaux inhibiteurs mpro du sars-cov-2 hautement sélectifs
MX2025006291A (es) Metodos de tratamiento de trastornos neurologicos
WO2025006726A3 (fr) Agonistes de tmem175, compositions et procédés d'utilisation
MX2024014831A (es) Derivados de acido sialico y metodos de uso de los mismos
WO2023164175A3 (fr) Protacs de malt1
CN107519102A (zh) 一种抑菌生发白醋洗发香波
WO2023215803A3 (fr) Inhibiteurs de cytochrome bd oxydase et leurs utilisations
MX2025009410A (es) Formas cristalinas o sales de un compuesto deuterado
WO2024019978A3 (fr) Combinaisons thérapeutiques et procédés
WO2024115797A3 (fr) Dérivés de dihydro-quinazoline, -benzothiazine et -benzoxazine et leur utilisation en tant qu'agonistes des récepteurs de l'orexine pour le traitement ou la prévention de maladies neurologiques
WO2023150702A3 (fr) Compositions et méthodes de traitement de connectivites
HUE024108T2 (en) Agricultural preparation, process for its preparation and application in the treatment of sowing
WO2022200553A3 (fr) Composition de nanoparticules de stimulation immunitaire
MX2023005031A (es) Compuesto degradante en un medicamento.

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24832976

Country of ref document: EP

Kind code of ref document: A2